<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Renal effects of ACE inhibitors in hypertension</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Renal effects of ACE inhibitors in hypertension</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Renal effects of ACE inhibitors in hypertension</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johannes FE Mann, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karl F Hilgers, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Elliott, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The effect of angiotensin-converting enzyme (ACE) inhibitors on kidney function in the patient with hypertension is related both to the glomerular actions of angiotensin II and the mechanism of autoregulation of the glomerular filtration rate (GFR) [<a href="#rid1">1</a>]. Angiotensin II constricts both the afferent (preglomerular) and efferent (postglomerular) arterioles but preferentially increases efferent resistance [<a href="#rid2">2</a>]. At least three factors may contribute to this response:</p><p class="bulletIndent1"><span class="glyph">●</span>The efferent arteriole has a smaller diameter in the basal state; as a result, further constriction at this site will produce a greater increase in resistance than at the afferent arteriole [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiotensin II stimulates the release of the vasodilator nitric oxide from the afferent arteriole, thereby minimizing constriction at this site [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiotensin II minimizes vasoconstriction at the afferent arteriole via the stimulation of angiotensin II type 2 receptors, which results in vasodilation through a cytochrome P450-dependent pathway [<a href="#rid4">4-6</a>].</p><p></p><p>The net effect of the more prominent increase in efferent tone is that the intraglomerular pressure is stable or increased, thereby tending to maintain or even raise the GFR. In addition to these arteriolar actions, angiotensin II constricts the mesangial cells, an effect that tends to lower the GFR by decreasing the surface area available for filtration.</p><p>An overview of the kidney effects of ACE inhibitors will be reviewed here. The use of ACE inhibitors and angiotensin receptor blockers (ARBs) in patients with kidney disease is presented in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">ANGIOTENSIN II AND AUTOREGULATION OF GFR</span><span class="headingEndMark"> — </span>As the kidney perfusion pressure is diminished (due for example to antihypertensive therapy), the kidney is initially able to maintain both blood flow and glomerular filtration via the phenomenon of autoregulation (<a class="graphic graphic_figure graphicRef57043" href="/z/d/graphic/57043.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>]. The first part of the autoregulatory response is decreased afferent (precapillary) arteriolar tone, thereby allowing more of the systemic pressure to be transmitted to the glomerulus. Afferent dilatation is mediated both by tubuloglomerular feedback and by a direct myogenic response. With more marked reductions in kidney perfusion pressure, renin release is stimulated; the ensuing increase in angiotensin II production maintains both intraglomerular pressure and the glomerular filtration rate (GFR) via a preferential increase in resistance at the efferent arteriole [<a href="#rid7">7</a>]. The net effect is that the GFR and renal blood flow do not begin to fall until these autoregulatory changes in arteriolar resistance are maximized.</p><p class="headingAnchor" id="H3"><span class="h1">PRIMARY HYPERTENSION</span><span class="headingEndMark"> — </span>In patients with primary hypertension, kidney perfusion pressure is elevated, and therefore maintenance of the glomerular filtration rate (GFR) is not as dependent upon angiotensin II. As a result, an angiotensin-converting enzyme (ACE) inhibitor generally induces little change in GFR in patients who have normal kidney function [<a href="#rid8">8</a>]. In comparison, some patients with a relatively recent onset of hypertension have increased angiotensin II activity, renal vasoconstriction, and a GFR below 80 mL/min. In this setting, an ACE inhibitor can raise the GFR by 10 to 30 mL/min, presumably due to reversal of angiotensin II-induced mesangial contraction [<a href="#rid8">8,9</a>].</p><p>The outcome may be different in patients who develop kidney disease due to benign nephrosclerosis. In this setting, an ACE inhibitor can lead to an acute decline in GFR due to intrarenal vascular disease via a mechanism similar to that in bilateral renal artery stenosis [<a href="#rid10">10</a>]. However, in one study of over 1000 Black patients with hypertensive kidney disease, the ACE inhibitor <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> retarded the progression of kidney disease better than the calcium channel blocker <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H23991796"><span class="h2">Angiotensin receptor blockers</span><span class="headingEndMark"> — </span>The kidney effects of angiotensin receptor blockers (ARBs) in people with hypertension have not been studied to the same extent and detail as for ACE inhibitors. Some studies in experimental animals reported differences in kidney effects between ACE inhibitors and ARBs due to different effects on kinins and/or effects mediated by different angiotensin receptor subtypes. However, most of the evidence in humans suggests that the kidney effects of ARBs are broadly similar to those of ACE inhibitors. This notion is supported by large outcome trials with head-to-head comparisons between ACE inhibitors and ARBs. These issues are discussed elsewhere in detail:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3815.html" rel="external">"Renin-angiotensin system inhibition in the treatment of hypertension", section on 'Angiotensin II receptor blockers'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Angiotensin II receptor blockers'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Long-term effects</span><span class="headingEndMark"> — </span>It remains uncertain whether ACE inhibitors offer preferential long-term protection of kidney function in patients with primary hypertension as they do in a variety of forms of chronic kidney disease [<a href="#rid12">12</a>] (see  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>). One study of 257 patients with primary hypertension suggested that there may be a lower rate of loss of GFR in patients who are treated with an ACE inhibitor compared with a beta blocker despite equivalent degrees of blood pressure control [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/3824.html" rel="external">"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">RENOVASCULAR HYPERTENSION</span><span class="headingEndMark"> — </span>The hemodynamic response to angiotensin-converting enzyme (ACE) inhibition in renal artery stenosis may be different from that with uncomplicated primary hypertension. In this setting, lowering the systemic blood pressure will, because of the stenotic lesion, tend to reduce the intraglomerular pressure below normal. Although the glomerular filtration rate (GFR) can be maintained by autoregulation, blocking angiotensin II formation with an ACE inhibitor will blunt this response and tend to reduce the GFR (<a class="graphic graphic_figure graphicRef57043" href="/z/d/graphic/57043.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>]. This effect is more pronounced in the presence of diuretic-induced volume depletion since the increase in baseline angiotensin II levels makes maintenance of the GFR more angiotensin II dependent [<a href="#rid7">7,14</a>].</p><p>The net effect is that between one-third and one-half of patients with renal artery stenosis will have a usually mild decline in GFR after the administration of an ACE inhibitor [<a href="#rid15">15</a>]. For similar reasons, bilateral renovascular disease should be strongly suspected in patients with hypertension who are not hypovolemic and in whom the plasma creatinine concentration rises after starting an ACE inhibitor. Although many of these patients will have renal artery stenosis, a similar change can occur with hypovolemia (often induced by diuretics) and with <strong>intrarenal</strong> vascular disease due to hypertensive nephrosclerosis or systemic vasculitis (such as polyarteritis nodosa) [<a href="#rid10">10,16</a>]. It has been estimated, for example, that of all patients with hypertension in whom an ACE inhibitor raises the plasma creatinine concentration, more than one-half will have renal artery stenosis, while most of the remaining patients have nephrosclerosis [<a href="#rid17">17</a>].</p><p>The decline in GFR induced by an ACE inhibitor typically occurs within the first few days after the onset of therapy since angiotensin II levels are rapidly reduced. As a result, the plasma creatinine concentration should be remeasured three to five days after the institution of therapy in patients with known renal artery stenosis and in those at high risk for the disease (as with severe hypertension in the presence of atherosclerotic vascular disease). (See  <a class="medical medical_review" href="/z/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension"</a>.)</p><p>When it occurs, the rise in the plasma creatinine concentration is usually mild and acceptable [<a href="#rid17">17,18</a>]. In one study, for example, 75 patients with known renovascular hypertension were randomly assigned to therapy with <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> plus <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a> or hydrochlorothiazide plus <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> and <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> [<a href="#rid18">18</a>]. A 0.3 mg/dL or larger increase in creatinine occurred in 20 percent of patients treated with enalapril (the mean reduction in GFR in this group was 23 mL/min), one-half of whom had preexisting kidney function impairment and one-third of whom had bilateral renal artery stenosis. Blood pressure control was slightly better in patients treated with enalapril.</p><p>The decline in GFR that may occur with ACE inhibitors is indicative of a decrease in intraglomerular pressure, a probable mechanism for protection against progression of kidney disease [<a href="#rid19">19</a>]. Patients with renal artery stenosis who are able to tolerate ACE inhibitor therapy may derive a similar benefit [<a href="#rid20">20-22</a>]. In one study of 621 patients with renal artery stenosis followed at a single referral center, ACE inhibitors were prescribed in 378 patients, and nearly all such patients tolerated therapy (92 percent overall and 78 percent of those with bilateral renal artery stenosis) [<a href="#rid20">20</a>]. Compared with those prescribed other therapy, those taking ACE inhibitors had a significantly lower mortality after controlling for possible confounders (hazard ratio 0.61, 95% CI 0.40-0.81). (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p>A large and persistent decline in kidney function resulting in a 30 percent or greater rise in serum creatinine (or 30 percent or greater fall in estimated GFR) occurs in less than 5 to 10 percent of cases. These patients generally require either institution of other antihypertensive agents that do not interfere with autoregulation (such as a calcium channel blocker) [<a href="#rid23">23</a>] or correction of the stenosis by angioplasty or surgery. Patients with severe bilateral disease may not tolerate any form of antihypertensive therapy, since an adequate intraglomerular pressure can be maintained only at very high systemic pressures (<a class="graphic graphic_figure graphicRef75208" href="/z/d/graphic/75208.html" rel="external">figure 2</a>) [<a href="#rid24">24</a>]. In this setting, the GFR falls because the intraglomerular pressure is reduced below the level at which it can be maintained by autoregulation. (See  <a class="medical medical_review" href="/z/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney"</a>.)</p><p>The ACE inhibitor-induced reduction in GFR in renovascular disease almost always resolves after cessation of therapy. In addition, the plasma creatinine concentration can often be returned toward the baseline level by discontinuation of diuretic therapy [<a href="#rid14">14</a>]. It has been suggested, however, that irreversible kidney failure can rarely occur [<a href="#rid25">25</a>]. How this might happen is not clear. In most such patients, the decline in kidney function was noted weeks to months after the ACE inhibitor was started, thereby making a cause-and-effect relationship uncertain. One possible mechanism is the development of renal artery thrombosis [<a href="#rid26">26</a>]. This complication has been reported primarily in patients with marked (≥95 percent) stenotic lesions who have an excessive reduction in blood pressure. It is therefore unclear if there was any specific predisposing effect of the ACE inhibitor.</p><p class="headingAnchor" id="H6"><span class="h2">Unilateral renal artery stenosis</span><span class="headingEndMark"> — </span>The effect in unilateral renal artery stenosis is more subtle. An ACE inhibitor may decrease the GFR in the stenotic kidney [<a href="#rid27">27,28</a>]. However, a substantial fall in the total GFR with a rise in the plasma creatinine concentration is usually not seen because of an equivalent increment in GFR in the contralateral kidney (due to removal of angiotensin II-induced renal vasoconstriction).</p><p class="headingAnchor" id="H7"><span class="h2">Risk of ischemic atrophy</span><span class="headingEndMark"> — </span>Even when the total GFR is relatively well maintained, there is a concern that hypofiltration and the fall in perfusion pressure might eventually lead to ischemic atrophy [<a href="#rid29">29</a>]. The risk of this complication and whether it is more likely to occur with an ACE inhibitor are currently unresolved. (See  <a class="medical medical_review" href="/z/d/html/3834.html" rel="external">"Treatment of unilateral atherosclerotic renal artery stenosis", section on 'Medical therapy'</a>.)</p><p>Prolonged ACE inhibitor or angiotensin receptor blocker (ARB) use may result in significant worsening of kidney function in a few patients [<a href="#rid30">30</a>], and one small study has suggested that discontinuing these agents in patients with advanced chronic kidney disease may improve kidney function [<a href="#rid31">31</a>]. However, a trial that randomly assigned such patients to withdrawal or continuation of ACE inhibitor or ARB found no difference in GFR decline or kidney failure at three years; in addition, cardiovascular events tended to be fewer in the continuation group [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H21519415"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The effect of angiotensin-converting enzyme (ACE) inhibitors on the glomerular filtration rate (GFR) in patients with hypertension is related both to the glomerular actions of angiotensin II and to the mechanism of autoregulation of the GFR. Angiotensin II constricts both the afferent (preglomerular) and efferent (postglomerular) arterioles but preferentially increases efferent resistance. The net effect of the more prominent increase in efferent tone is that the intraglomerular pressure is stable or increased, thereby tending to maintain or even raise the GFR. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As the kidney perfusion pressure is diminished, the kidney is initially able to maintain both blood flow and the GFR via the phenomenon of autoregulation (<a class="graphic graphic_figure graphicRef57043" href="/z/d/graphic/57043.html" rel="external">figure 1</a>). The initial autoregulatory response to a decrease in systemic arterial pressure is decreased afferent arteriolar tone, thereby allowing more of the systemic pressure to be transmitted to the glomerulus. However, with more marked reductions in kidney perfusion pressure, renin-mediated increases in angiotensin II production maintain both intraglomerular pressure and the GFR via a preferential increase in resistance at the efferent arteriole. (See <a class="local">'Angiotensin II and autoregulation of GFR'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>These concepts are critical for understanding the effects of ACE inhibitors on GFR in various forms of hypertension:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with primary hypertension, kidney perfusion pressure is elevated, and therefore maintenance of the GFR is not as dependent upon angiotensin II. As a result, an ACE inhibitor generally induces little change in GFR in patients who have normal kidney function. (See <a class="local">'Primary hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The outcome may be different in patients who develop kidney disease due to benign nephrosclerosis. In this setting, an ACE inhibitor can lead to an acute decline in GFR due to intrarenal vascular disease via a mechanism similar to that in bilateral renal artery stenosis, discussed above. (See <a class="local">'Primary hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with renovascular hypertension, lowering the systemic blood pressure with an ACE inhibitor will, because of the stenotic lesion, tend to reduce the intraglomerular pressure below normal. Although the GFR could be maintained by autoregulation, blocking angiotensin II formation with an ACE inhibitor will blunt this response and tend to reduce the GFR (<a class="graphic graphic_figure graphicRef57043" href="/z/d/graphic/57043.html" rel="external">figure 1</a>). (See <a class="local">'Renovascular hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Between one-third and one-half of patients with renal artery stenosis will have a usually mild decline in GFR, occurring within a few days after the administration of an ACE inhibitor. A large decline in kidney function occurs in less than 5 to 10 percent of cases. The ACE inhibitor-induced reduction in GFR in renovascular disease almost always resolves after cessation of therapy. (See <a class="local">'Renovascular hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral renovascular disease should be strongly suspected in patients with hypertension in whom the plasma creatinine concentration rises by more than 30 percent within a week after starting an ACE inhibitor. Although many of these patients will have renal artery stenosis, a similar change can occur with intrarenal vascular disease due to hypertensive nephrosclerosis or systemic vasculitis (such as polyarteritis nodosa) and in hypovolemic patients. (See <a class="local">'Renovascular hypertension'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Braam B, Koomans HA. Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens 1996; 5:89.</a></li><li><a class="nounderline abstract_t">Denton KM, Fennessy PA, Alcorn D, Anderson WP. Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli. Am J Physiol 1992; 262:F367.</a></li><li><a class="nounderline abstract_t">Ito S, Arima S, Ren YL, et al. Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 1993; 91:2012.</a></li><li><a class="nounderline abstract_t">Arima S, Endo Y, Yaoita H, et al. Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 1997; 100:2816.</a></li><li><a class="nounderline abstract_t">Arima S. Role of angiotensin II and endogenous vasodilators in the control of glomerular hemodynamics. Clin Exp Nephrol 2003; 7:172.</a></li><li><a class="nounderline abstract_t">Kohagura K, Endo Y, Ito O, et al. Endogenous nitric oxide and epoxyeicosatrienoic acids modulate angiotensin II-induced constriction in the rabbit afferent arteriole. Acta Physiol Scand 2000; 168:107.</a></li><li><a class="nounderline abstract_t">Hall JE, Guyton AC, Jackson TE, et al. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 1977; 233:F366.</a></li><li><a class="nounderline abstract_t">Hollenberg NK, Swartz SL, Passan DR, Williams GH. Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension. N Engl J Med 1979; 301:9.</a></li><li><a class="nounderline abstract_t">Reams GP, Bauer JH. Effect of lisinopril monotherapy on renal hemodynamics. Am J Kidney Dis 1988; 11:499.</a></li><li><a class="nounderline abstract_t">Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991; 115:513.</a></li><li><a class="nounderline abstract_t">Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719.</a></li><li><a class="nounderline abstract_t">Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021; 99:559.</a></li><li><a class="nounderline abstract_t">Himmelmann A, Hansson L, Hansson BG, et al. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press 1995; 4:85.</a></li><li><a class="nounderline abstract_t">Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med 1985; 103:222.</a></li><li><a class="nounderline abstract_t">van de Ven PJ, Beutler JJ, Kaatee R, et al. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 1998; 53:986.</a></li><li><a class="nounderline abstract_t">Jaichenko J, Fudin R, Shostak A, Gotloib L. Use of angiotensin-converting enzyme inhibitors in patients with diabetic and nondiabetic chronic renal diseases: a need for reassessment. Nephron 1998; 80:367.</a></li><li><a class="nounderline abstract_t">Mimran A, Ribstein J, DuCailar G. Converting enzyme inhibitors and renal function in essential and renovascular hypertension. Am J Hypertens 1991; 4:7S.</a></li><li><a class="nounderline abstract_t">Franklin SS, Smith RD. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med 1985; 79:14.</a></li><li><a class="nounderline abstract_t">Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2011; 13:667.</a></li><li><a class="nounderline abstract_t">Chrysochou C, Foley RN, Young JF, et al. Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant 2012; 27:1403.</a></li><li><a class="nounderline abstract_t">Losito A, Errico R, Santirosi P, et al. Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant 2005; 20:1604.</a></li><li><a class="nounderline abstract_t">Losito A, Gaburri M, Errico R, et al. Survival of patients with renovascular disease and ACE inhibition. Clin Nephrol 1999; 52:339.</a></li><li><a class="nounderline abstract_t">Miyamori I, Yasuhara S, Matsubara T, et al. Comparative effects of captopril and nifedipine on split renal function in renovascular hypertension. Am J Hypertens 1988; 1:359.</a></li><li><a class="nounderline abstract_t">Textor SC, Novick AC, Tarazi RC, et al. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med 1985; 102:308.</a></li><li><a class="nounderline abstract_t">Devoy MA, Tomson CR, Edmunds ME, et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992; 232:493.</a></li><li><a class="nounderline abstract_t">Hannedouche T, Godin M, Fries D, Fillastre JP. Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension. Nephron 1991; 57:230.</a></li><li><a class="nounderline abstract_t">Wenting GJ, Tan-Tjiong HL, Derkx FH, et al. Splint renal function after captopril in unilateral renal artery stenosis. Br Med J (Clin Res Ed) 1984; 288:886.</a></li><li><a class="nounderline abstract_t">Jackson B, McGrath BP, Matthews PG, et al. Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension. Hypertension 1986; 8:650.</a></li><li><a class="nounderline abstract_t">Hricik DE, Dunn MJ. Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses. J Am Soc Nephrol 1990; 1:845.</a></li><li><a class="nounderline abstract_t">Onuigbo MA, Onuigbo NT. Use of ultrahigh RAAS blockade: implications for exacerbation of renal failure. Kidney Int 2006; 69:194.</a></li><li><a class="nounderline abstract_t">Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010; 25:3977.</a></li><li><a class="nounderline abstract_t">Bhandari S, Mehta S, Khwaja A, et al. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med 2022; 387:2021.</a></li></ol></div><div id="topicVersionRevision">Topic 3873 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8834166" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Renal responses to antagonism of the renin-angiotensin system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558155" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8486771" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9389747" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14586712" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Role of angiotensin II and endogenous vasodilators in the control of glomerular hemodynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691787" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Endogenous nitric oxide and epoxyeicosatrienoic acids modulate angiotensin II-induced constriction in the rabbit afferent arteriole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/920806" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Control of glomerular filtration rate by renin-angiotensin system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/221809" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2837083" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of lisinopril monotherapy on renal hemodynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1883120" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11386927" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33637203" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599759" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3893255" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Captopril-induced renal insufficiency and the role of sodium balance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551408" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9807055" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Use of angiotensin-converting enzyme inhibitors in patients with diabetic and nondiabetic chronic renal diseases: a need for reassessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2009153" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Converting enzyme inhibitors and renal function in essential and renovascular hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2996342" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21896148" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Angiotensin-converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21993376" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870215" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604640" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Survival of patients with renovascular disease and ACE inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3063285" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparative effects of captopril and nifedipine on split renal function in renovascular hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3970470" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1474349" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2020353" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6423129" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Splint renal function after captopril in unilateral renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3015794" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2103846" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374445" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Use of ultrahigh RAAS blockade: implications for exacerbation of renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820248" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36326117" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
